芎黄合剂治疗重症肺炎合并胃肠功能障碍临床观察

Xionghuang Mixture for Severe Pneumonia Complicated with Gastrointestinal Dysfunction

目的探讨芎黄合剂治疗重症肺炎合并胃肠功能障碍患者的临床疗效。方法将60例重症肺炎合并胃肠功能障碍的患者随机分为对照组和芎黄合剂组,每组30例。对照组采用西医常规治疗,芎黄合剂组在对照组治疗的基础上加用芎黄合剂,疗程均为14 d。比较治疗前及治疗第7、14 d两组炎症因子水平(血清CRP、PCT、IL-6和IL-8)、临床肺部感染评分(CPIS)、胃肠功能障碍评分(GIDS)及第28 d死亡率。结果治疗后第7、14 d两组患者炎症水平、CPIS及GIDS均较本组治疗前明显下降(P<0.05,P<0.01);第7、14 d芎黄合剂组的上述指标较对照组同期降低(P<0.05,P<0.01);第28 d芎黄合剂组病死率[6.7%(2/30)]低于对照组[16.7%(5/30)],但两者比较差异无统计学意义(P>0.05)。结论芎黄合剂能降低重症肺炎合并胃肠功能障碍患者炎症水平,促进患者胃肠功能恢复。

Objective To observe the clinical efficacy of Xionghuang Mixture（ XHM） in treatment of severe pneumonia complicated with gastrointestinal dysfunction. Methods Sixty patients with severe pneumonia complicated with gastrointestinal dysfunction were randomly assigned to the control group and the XHM group,30 in each group. Patients in the control group were treated with standard Western medical method,while those in the XHM group additionally took XHM. The therapeutic course lasted for 14 days. The levels of inflammation factors（ serum CRP,PCT,IL-6,and IL-8）,clinical pulmonary infection score（ CPIS）,and gastrointestinal dysfunction score（ GIDS） were compared between the two groups before treatment,and at day 7 and 14 after treatment. The 28-day mortality was also detected. Results The inflammation levels,CPIS and GIDS were all decreased significantly at day 7 and 14 after treatment in both groups（P〈0. 05,P〈0. 01）. The indices mentioned above decreased at day 7 and 14 in the XHM group,as compared with the control group（P〈0. 05,P〈0. 01）. The 28-day mortality was lower in the XHM group [6. 7%（ 2/30） ],as compared with the control group [16. 7%（ 5/30）,P〈0. 05]. Conclusion XHM could decrease the inflammation level and promote the recovery of gastrointestinal function of patients with severe pneumonia complicated with gastrointestinal dysfunction.